These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 15723328)

  • 1. "Strong reasons make strong actions"--The antiviral efficacy of NS3/4A protease inhibitors.
    Lemon SM; Yi M; Li K
    Hepatology; 2005 Mar; 41(3):671-4. PubMed ID: 15723328
    [No Abstract]   [Full Text] [Related]  

  • 2. Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C.
    Reiser M; Hinrichsen H; Benhamou Y; Reesink HW; Wedemeyer H; Avendano C; Riba N; Yong CL; Nehmiz G; Steinmann GG
    Hepatology; 2005 Apr; 41(4):832-5. PubMed ID: 15732092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus.
    Lamarre D; Anderson PC; Bailey M; Beaulieu P; Bolger G; Bonneau P; Bös M; Cameron DR; Cartier M; Cordingley MG; Faucher AM; Goudreau N; Kawai SH; Kukolj G; Lagacé L; LaPlante SR; Narjes H; Poupart MA; Rancourt J; Sentjens RE; St George R; Simoneau B; Steinmann G; Thibeault D; Tsantrizos YS; Weldon SM; Yong CL; Llinàs-Brunet M
    Nature; 2003 Nov; 426(6963):186-9. PubMed ID: 14578911
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Viral kinetics in patients with chronic hepatitis C treated with the serine protease inhibitor BILN 2061.
    Herrmann E; Zeuzem S; Sarrazin C; Hinrichsen H; Benhamou Y; Manns MP; Reiser M; Reesink H; Calleja JL; Forns X; Steinmann GG; Nehmiz G
    Antivir Ther; 2006; 11(3):371-6. PubMed ID: 16759054
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Virology: fresh assault on hepatitis C.
    Rice CM
    Nature; 2003 Nov; 426(6963):129-31. PubMed ID: 14578912
    [No Abstract]   [Full Text] [Related]  

  • 6. Bismacrocyclic inhibitors of hepatitis C NS3/4a protease.
    McCauley JA; Rudd MT; Nguyen KT; McIntyre CJ; Romano JJ; Bush KJ; Varga SL; Ross CW; Carroll SS; DiMuzio J; Stahlhut MW; Olsen DB; Lyle TA; Vacca JP; Liverton NJ
    Angew Chem Int Ed Engl; 2008; 47(47):9104-7. PubMed ID: 18925594
    [No Abstract]   [Full Text] [Related]  

  • 7. Discovery of novel potent and selective dipeptide hepatitis C virus NS3/4A serine protease inhibitors.
    Raboisson P; Lin TI; Kock Hd; Vendeville S; Vreken WV; McGowan D; Tahri A; Hu L; Lenz O; Delouvroy F; Surleraux D; Wigerinck P; Nilsson M; Rosenquist S; Samuelsson B; Simmen K
    Bioorg Med Chem Lett; 2008 Sep; 18(18):5095-100. PubMed ID: 18722116
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The design of a potent inhibitor of the hepatitis C virus NS3 protease: BILN 2061--from the NMR tube to the clinic.
    Tsantrizos YS
    Biopolymers; 2004; 76(4):309-23. PubMed ID: 15386268
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis of BILN 2061, an HCV NS3 protease inhibitor with proven antiviral effect in humans.
    Faucher AM; Bailey MD; Beaulieu PL; Brochu C; Duceppe JS; Ferland JM; Ghiro E; Gorys V; Halmos T; Kawai SH; Poirier M; Simoneau B; Tsantrizos YS; Llinàs-Brunet M
    Org Lett; 2004 Aug; 6(17):2901-4. PubMed ID: 15330643
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resistance of hepatitis C virus to NS3-4A protease inhibitors: mechanisms of drug resistance induced by R155Q, A156T, D168A and D168V mutations.
    Courcambeck J; Bouzidi M; Perbost R; Jouirou B; Amrani N; Cacoub P; Pèpe G; Sabatier JM; Halfon P
    Antivir Ther; 2006; 11(7):847-55. PubMed ID: 17302247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mapping natural polymorphisms of hepatitis C virus NS3/4A protease and antiviral resistance to inhibitors in worldwide isolates.
    López-Labrador FX; Moya A; Gonzàlez-Candelas F
    Antivir Ther; 2008; 13(4):481-94. PubMed ID: 18672527
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Naturally occurring NS3-protease-inhibitor resistant mutant A156T in the liver of an untreated chronic hepatitis C patient.
    Cubero M; Esteban JI; Otero T; Sauleda S; Bes M; Esteban R; Guardia J; Quer J
    Virology; 2008 Jan; 370(2):237-45. PubMed ID: 18006035
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibitors of hepatitis C virus NS3.4A protease 2. Warhead SAR and optimization.
    Perni RB; Pitlik J; Britt SD; Court JJ; Courtney LF; Deininger DD; Farmer LJ; Gates CA; Harbeson SL; Levin RB; Lin C; Lin K; Moon YC; Luong YP; O'Malley ET; Rao BG; Thomson JA; Tung RD; Van Drie JH; Wei Y
    Bioorg Med Chem Lett; 2004 Mar; 14(6):1441-6. PubMed ID: 15006379
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel robust hepatitis C virus mouse efficacy model.
    Zhu Q; Oei Y; Mendel DB; Garrett EN; Patawaran MB; Hollenbach PW; Aukerman SL; Weiner AJ
    Antimicrob Agents Chemother; 2006 Oct; 50(10):3260-8. PubMed ID: 17005803
    [TBL] [Abstract][Full Text] [Related]  

  • 15. P2-P4 macrocyclic inhibitors of hepatitis C virus NS3-4A serine protease.
    Arasappan A; Njoroge FG; Chen KX; Venkatraman S; Parekh TN; Gu H; Pichardo J; Butkiewicz N; Prongay A; Madison V; Girijavallabhan V
    Bioorg Med Chem Lett; 2006 Aug; 16(15):3960-5. PubMed ID: 16730985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-throughput cell-based screening for hepatitis C virus NS3/4A protease inhibitors.
    Lee JC; Yu MC; Lien TW; Chang CF; Hsu JT
    Assay Drug Dev Technol; 2005 Aug; 3(4):385-92. PubMed ID: 16180993
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of placebo: is it a boon or bane?
    Girish C
    Gastroenterology; 2005 Mar; 128(3):805. PubMed ID: 15765430
    [No Abstract]   [Full Text] [Related]  

  • 18. The resistance mutation R155K in the NS3/4A protease of hepatitis C virus also leads the virus to escape from HLA-A*68-restricted CD8 T cells.
    Salloum S; Kluge SF; Kim AY; Roggendorf M; Timm J
    Antiviral Res; 2010 Aug; 87(2):272-5. PubMed ID: 20488208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trial watch: Protease inhibitors show promise against HCV.
    Nat Rev Drug Discov; 2009 Jan; 8(1):11. PubMed ID: 19116621
    [No Abstract]   [Full Text] [Related]  

  • 20. Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients.
    Hinrichsen H; Benhamou Y; Wedemeyer H; Reiser M; Sentjens RE; Calleja JL; Forns X; Erhardt A; Crönlein J; Chaves RL; Yong CL; Nehmiz G; Steinmann GG
    Gastroenterology; 2004 Nov; 127(5):1347-55. PubMed ID: 15521004
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.